AI Earnings Predictions for Century Therapeutics Inc. (IPSC)

EX-99.1

2 tm2622911d1_ex99-1.htm

EXHIBIT 99.1

Exhibit 99.1

Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

·Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026

·CNTY-813 preclinical data from oral presentation at ADA 2026 showed durable glucose control in vivo, immune evasion, and manufacturing success at clinical scale, advancing its potential as a functional cure for T1D

·Upcoming oral presentations at European Association for the Study of Diabetes (EASD 2026) and Breakthrough T1D® Clinical & Research Congress 2026 highlighting CNTY-813

·Company remains on track to advance CNTY-308, a CD19-targeted CAR-iT cell therapy with Allo-EvasionTM 5.0 into the clinic this year

·Cash runway into 1Q 2029 with cash, cash equivalents, and investments of $197.2 million as of June 30, 2026

PHILADELPHIA, August 12, 2026 –– Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including T1D, and cancer, today reported financial results for the second quarter ended June 30, 2026, and recent business highlights.

"We are executing with speed against key development milestones, reinforcing our confidence in delivering on our ambition to transform diseases like T1D by creating functional cures at scale," said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics. "With CNTY-813, our preclinical data at ADA 2026 continue to support its potential as a functional T1D cure, and we have established our Phase 1 manufacturing process, demonstrating consistent product quality across independent batches. Our recent pre-IND meeting with the FDA builds on that progress yielding alignment with the FDA on our nonclinical data package, manufacturing strategy, and proposed Phase 1/2 trial design, keeping CNTY-813's IND submission on track for the fourth quarter of 2026. In addition, CNTY-308 remains on track to enter the clinic in 2026."

Second Quarter 2026 and Recent Highlights

Pre-IND meeting with the FDA supports regulatory and

initial clinical path for CNTY-813

·Following a recent pre-IND meeting with the FDA, Century remains on track to submit an IND for CNTY-813 in the fourth quarter of 2026.

·Century and the FDA reached general alignment on the nonclinical data package, the proposed Phase 1 manufacturing process and the Phase 1/2 clinical trial design which includes alignment on:

oGLP toxicology study, which is ongoing and on track to support the planned submission.

oPhase 1 manufacturing process and testing plan that includes cell bank, intermediate, and final drug product release tests.

oProposed Phase 1/2 clinical trial including dosing and patient eligibility criteria.

·New preclinical data further support CNTY-813 as a potential functional cure for T1D; data were presented at the 2026 American Diabetes Association (ADA) Scientific Sessions in June (link to press release HERE).

Data demonstrated key advancements for CNTY-813 including:

oDurable in vivo glucose control maintained for more than eight months and immune evasion under allogeneic immune pressure without immunosuppression.

oConsistent and scalable product quality and performance at Phase 1 clinical trial scale.

·IND submission remains on track for 4Q 2026, with initial clinical data expected in 2H 2027.

CNTY-813 Phase 1 manufacturing process established

·Century has established its Phase 1 clinical manufacturing bioreactor process for CNTY-813, demonstrating consistent process performance and product quality, endocrine purity, and optimal islet cell content across independent batches run at the same scale intended for the Phase 1 clinical trial.

CNTY-813 preclinical data selected for oral presentations

at congresses this fall

·62nd Annual Meeting of the European Association for the Study of Diabetes (EASD 2026; Milan, Italy; Presentation #225, Paris Hall, October 2nd, 2026, 10-11 AM CEST)

·Breakthrough T1D® Clinical & Research Congress 2026 (CRC 2026; Philadelphia, Pennsylvania; Presentation #341, Hall 1, October 9th, 2026, 3:50- 4:50 PM EST)

·Both presentations will highlight CNTY-813, Century's iPSC-derived islet replacement therapy program engineered with Allo-Evasion™ 5.0 for patients with T1D.

CNTY-308

clinical trial planned to initiate in 2026

·Century remains on track, after aligning on nonclinical, manufacturing and Phase 1 clinical trial parameters with health authorities, to complete IND-enabling activities for CNTY-308, a CD19-targeted CD4⁺/CD8⁺ αβ CAR-iT cell therapy engineered with Allo-Evasion™ 5.0 for B-cell-mediated diseases. CNTY-308 is anticipated to enter the clinic in 2026.

·Preclinical data showed functional comparability to primary CAR-T cells, including target-driven proliferation, cytokine secretion, an

EX-99.1

2 tm2614312d1_ex99-1.htm

EXHIBIT 99.1

Exhibit 99.1

Century Therapeutics Reports First Quarter Financial Results and Business Updates

·CNTY-813, Century’s type 1 diabetes iPSC-derived islet therapy with functional-cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027

·Upcoming oral presentation at the American Diabetes Association (ADA) annual Scientific Sessions highlighting CNTY-813 preclinical data on June 8, 2026

·On track to advance CNTY-308, Century’s CD19-targeted CAR-iT cell therapy, into the clinic this year

·Cash runway into 1Q 2029 with cash, cash equivalents, and marketable securities of $217.0 million as of March 31, 2026

PHILADELPHIA, May 13, 2026 -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today reported financial results for the first quarter ended March 31, 2026, and recent business highlights.

“We are executing our pipeline with discipline to deliver an iPSC-derived islet replacement therapy to patients. The progress of CNTY-813 highlights what Century can achieve pairing our Allo-Evasion™ engineering with a scalable iPSC platform,” said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics. “In a relatively short time since initiating this program, we have advanced CNTY-813 into IND-enabling studies on a timeline we believe is highly competitive with leading efforts in the field. With an IND submission expected in the fourth quarter of 2026 and initial clinical data anticipated in the second half of 2027, our focus is clear: to deliver a differentiated, patient-centric, potentially curative approach for people with type 1 diabetes while continuing to expand our autoimmune disease portfolio with CNTY-308.”

First Quarter 2026 and Recent Highlights

Pipeline

·CNTY-813, Century’s priority program in type 1 diabetes, reflects strong execution: During Q1 2026, the company made meaningful progress across key IND-enabling activities, including non-clinical development, manufacturing, and regulatory readiness, supporting a clear line of sight to the clinic. Progress to date includes compelling preclinical data showing durable glucose control and immune protection, completion of GMP Master Cell Bank manufacturing, and recent FDA engagement, further de-risking the program. Building on this momentum, Century expects to submit an IND in 4Q 2026, subject to completion of remaining studies, and anticipates initial clinical data in the second half of 2027.

·Upcoming ADA presentation highlights Century’s islet cell replacement therapy engineered with Allo-Evasion™ 5.0: Century will deliver an oral presentation at the ADA 86th Scientific Sessions titled “CNTY-813: Scalable Production of Allo-Evasion™ 5.0-Engineered iPSC Beta Islets for Off-the-Shelf Cell Therapies” (Oral Presentation 1318-OR; Monday, June 8, 2026), highlighting scalable production of iPSC-derived islets with robust endocrine function and the demonstrated ability to evade the host immune system.

·CNTY-308 to progress through IND-enabling studies with clinical trial planned to initiate in 2026: Century remains on track to complete IND-enabling activities for CNTY-308 and initiate clinical testing in 2026, pending regulatory clearance. CNTY-308 is a CD19-targeted

CD4⁺/CD8⁺

αβ CAR-iT cell therapy engineered with Allo-Evasion™ 5.0 for B-cell-mediated diseases. Previously presented preclinical data showed functional comparability to primary CAR-T cells, including target-driven proliferation, cytokine secretion, and durable persistence. Collectively, these results and the expanding clinical validation of CAR-T therapy support Century’s confidence that CNTY-308 could deliver autologous-like benefits in an allogeneic, patient-centric format designed to broaden access.

Corporate

·As previously disclosed, completed oversubscribed $135 million private placement financing in January 2026 (HERE for more details).

First Quarter 2026 Financial Results

·Cash Position: Cash, cash equivalents, and marketable securities were $217.0 million as of March 31, 2026, as compared to $117.1 million as of December 31, 2025. Net cash used in operations was $25.3 million for the quarter ended March 31, 2026, compared to net cash used in operations of $34.6 million for the quarter ended March 31, 2025. The company estimates its cash, cash equivalents, and investments as of March 31, 2026 will support operations into the first quarter of 2029.

·Research and Development (R&D) Expenses: R&D expenses were $17.1 million for the quarter ended March 31, 2026, compared to $26.6 million for the same period in 2025. The decrease was primarily the result of a reduction in personnel and lower clinical trial spending.

·General and Administrative (G&A) Expenses: G&A expenses were $6.6 million for quarter ended March 31, 2026,

false 0001850119

0001850119

2026-03-12 2026-03-12

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 12, 2026

Century Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-40498

84-2040295

(State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(I.R.S. Employer

Identification No.)

25 North 38th Street, 11th Floor

Philadelphia, Pennsylvania

19104

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (267) 817-5790

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name of Exchange on Which Registered

Common Stock, par value $0.0001 per share

IPSC

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition

On March 12, 2026, Century Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure

On March 12, 2026, the Company updated information reflected in a slide presentation, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.

The information contained in this Item 7.01 (including Exhibit 99.2) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit

No.

Document

99.1

Press Release of Century Therapeutics, Inc., dated March 12, 2026

99.2

Investor Presentation of Century Therapeutics, Inc., dated March 12, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CENTURY

THERAPEUTICS, INC.

By: /s/ Brent Pfeiffenberger, Pharm.D.

Name: Brent Pfeiffenberger, Pharm.D.

Title: President and Chief Executive Officer

Date: March 12, 2026